Client News
Destiny Pharma: Publication of new data on NTCD-M3 confirms potential as an effective treatment for prevention of C. difficile infections
26th July 2022
Marinomed to pause issuing of tranches of Convertible Notes Funding Program to Nice & Green
21st July 2022
iOmx Therapeutics Announces the Appointment of Three New Supervisory Board Members
20th July 2022
CEVEC’s license partner RZNOMICS Inc. receives approval to initiate clinical development of CAP® Ad Technology-produced gene therapy vector in liver cancer patients
13th July 2022
VisionHealth and Boehringer Ingelheim: Digital therapy support for asthma and COPD
12th July 2022
Destiny Pharma receives award from the Cystic Fibrosis Foundation
12th July 2022
Andera Partners strengthens its Life Sciences team with a new partner
7th July 2022
There is no more content to load